NAPROXEN SODIUM TABLETS
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
31-01-2012
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
NAPROXEN SODIUM
Tilgængelig fra:
VITA HEALTH PRODUCTS INC
ATC-kode:
M01AE02
INN (International Name):
NAPROXEN
Dosering:
220MG
Lægemiddelform:
TABLET
Sammensætning:
NAPROXEN SODIUM 220MG
Indgivelsesvej:
ORAL
Enheder i pakken:
24/100/250/500
Recept type:
OTC
Terapeutisk område:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Produkt oversigt:
Active ingredient group (AIG) number: 0113934003; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2012-01-30
Produktets egenskaber
_Page 1 of 35_
PRODUCT MONOGRAPH
NAPROXEN SODIUM TABLETS
NAPROXEN SODIUM CAPLETS
NAPROXEN SODIUM TABLETS USP, 220 MG
Non-steroidal anti-inflammatory drug
Analgesic, Antipyretic
Vita Health Products Inc.
150 Beghin Avenue, Winnipeg
Manitoba, Canada R2J 3W2
Date of Preparation:
January 26, 2012
Control No.: 134246
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.............................................................................3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................
6
DRUG INTERACTIONS
.........................................................................................................................
9
DOSAGE AND ADMINISTRATION
...................................................................................................11
OVERDOSAGE
.....................................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................12
STORAGE AND STABILITY
...............................................................................................................13
SPECIAL HANDLING INSTRUCTIONS
............................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................................14
PART II:
Læs hele dokumentet
